KEMPHARM
KemPharm is a development-stage biopharmaceutical company focused on the discovery and development of new, safer therapies in the areas of pain, ADHD, and other CNS diseases. The company’s primary efforts include the development of safer, abuse-resistant opioid pain relievers. Its drug discovery and development platform is based on its proprietary Ligand Activated Therapy (LAT) approach. KemPharm uses its patent-applied technology to improve existing drugs and shorten the development timeline while still maintaining a strong intellectual property position within each therapeutic area.
KEMPHARM
Industry:
Biotechnology Pharmaceutical Therapeutics
Founded:
2006-01-01
Address:
Orlando, Florida, United States
Country:
United States
Website Url:
http://www.kempharm.com
Total Employee:
11+
Status:
Active
Contact:
888.958.1253
Email Addresses:
[email protected]
Total Funding:
75.75 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager WordPress Content Delivery Network
Similar Organizations
Aclaris Therapeutics
Aclaris Therapeutics is a specialty pharmaceutical company engaged in developing dermatologic therapies.
Apellis Pharmaceuticals
Apellis Pharmaceuticals focuses on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.
AVEO Oncology
AVEO is a biopharmaceutical company that offers drug development strategies for targeted cancer therapeutics.
FORMA Therapeutics
FORMA Therapeutics is a biopharmaceutical company focused on the discovery, development, and commercialization of transformative medicines.
Imvax
Imvax is a biotechnology company focused on the development of novel patient-specific vaccines and immunotherapy strategies.
Pliant Therapeutics
Pliant Therapeutics focuses on discovering, developing, and commercializing breakthrough treatments for fibrotic diseases.
Revagenix
Revagenix is a biopharmaceutical company discovering and developing therapies to address medical needs.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Deerfield
Deerfield investment in Debt Financing - KemPharm
BP Growth Partners
BP Growth Partners investment in Series B - KemPharm
BP Growth Partners
BP Growth Partners investment in Series A - KemPharm
Key Employee Changes
| Date | New article |
|---|---|
| 2022-08-09 | KemPharm Appoints Nichol Ochsner as Vice President, Investor Relations and Corporate Communications |
Official Site Inspections
http://www.kempharm.com Semrush global rank: 7.75 M Semrush visits lastest month: 437
Unable to get host informations!!!
